SCYNEXIS Valuation

Is SCYX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SCYX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SCYX ($1.2) is trading below our estimate of fair value ($44.2)

Significantly Below Fair Value: SCYX is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SCYX?

Key metric: As SCYX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SCYX. This is calculated by dividing SCYX's market cap by their current revenue.
What is SCYX's PS Ratio?
PS Ratio5.3x
SalesUS$8.57m
Market CapUS$45.16m

Price to Sales Ratio vs Peers

How does SCYX's PS Ratio compare to its peers?

The above table shows the PS ratio for SCYX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average31.6x
PVCT Provectus Biopharmaceuticals
69.6xn/aUS$47.8m
IRD Opus Genetics
3.8x62.0%US$31.1m
IGC IGC Pharma
23.3x10.1%US$27.3m
NTRB Nutriband
29.6xn/aUS$54.8m
SCYX SCYNEXIS
5.3x30.8%US$45.2m

Price-To-Sales vs Peers: SCYX is good value based on its Price-To-Sales Ratio (5.3x) compared to the peer average (31.6x).


Price to Sales Ratio vs Industry

How does SCYX's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

74 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$3.83b
PRGO Perrigo
0.9x3.4%US$3.69b
BHC Bausch Health Companies
0.3x1.5%US$3.01b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.58b
SCYX 5.3xIndustry Avg. 2.5xNo. of Companies74PS048121620+
74 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SCYX is expensive based on its Price-To-Sales Ratio (5.3x) compared to the US Pharmaceuticals industry average (2.5x).


Price to Sales Ratio vs Fair Ratio

What is SCYX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SCYX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.3x
Fair PS Ratio1.5x

Price-To-Sales vs Fair Ratio: SCYX is expensive based on its Price-To-Sales Ratio (5.3x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SCYX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.20
US$6.67
+455.6%
14.1%US$8.00US$6.00n/a3
Nov ’25US$1.34
US$6.67
+399.4%
14.1%US$8.00US$6.00n/a3
Oct ’25US$1.43
US$6.67
+366.2%
14.1%US$8.00US$6.00n/a3
Sep ’25US$1.46
US$6.88
+370.9%
13.0%US$8.00US$6.00n/a4
Aug ’25US$2.04
US$6.88
+237.0%
13.0%US$8.00US$6.00n/a4
Jul ’25US$1.95
US$6.88
+252.6%
13.0%US$8.00US$6.00n/a4
Jun ’25US$2.42
US$6.88
+184.7%
13.0%US$8.00US$6.00n/a4
May ’25US$1.72
US$6.88
+299.7%
13.0%US$8.00US$6.00n/a4
Apr ’25US$1.49
US$6.88
+361.4%
13.0%US$8.00US$6.00n/a4
Mar ’25US$1.62
US$7.13
+339.8%
10.4%US$8.00US$6.00n/a4
Feb ’25US$2.11
US$7.13
+237.7%
10.4%US$8.00US$6.00n/a4
Jan ’25US$2.23
US$8.13
+264.3%
14.0%US$10.00US$7.00n/a4
Dec ’24US$1.72
US$8.13
+372.4%
14.0%US$10.00US$7.00n/a4
Nov ’24US$1.78
US$9.90
+456.2%
27.2%US$15.00US$7.50US$1.345
Oct ’24US$2.28
US$9.90
+334.2%
27.2%US$15.00US$7.50US$1.435
Sep ’24US$3.65
US$11.80
+223.7%
22.4%US$15.00US$9.00US$1.465
Aug ’24US$2.92
US$11.40
+290.4%
26.4%US$15.00US$8.00US$2.045
Jul ’24US$2.95
US$11.40
+286.4%
26.4%US$15.00US$8.00US$1.955
Jun ’24US$2.62
US$11.40
+335.1%
26.4%US$15.00US$8.00US$2.425
May ’24US$3.10
US$11.40
+267.7%
26.4%US$15.00US$8.00US$1.725
Apr ’24US$3.00
US$11.20
+273.3%
28.5%US$15.00US$8.00US$1.495
Mar ’24US$1.73
US$10.60
+512.7%
34.1%US$15.00US$7.00US$1.625
Feb ’24US$1.71
US$15.00
+777.2%
54.8%US$30.00US$7.00US$2.115
Jan ’24US$1.56
US$15.00
+861.5%
54.8%US$30.00US$7.00US$2.235
Dec ’23US$2.12
US$15.00
+607.5%
54.8%US$30.00US$7.00US$1.725
Nov ’23US$2.23
US$18.00
+707.2%
56.5%US$30.00US$7.00US$1.785

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies